Stephanie Sutton

The future of pharmaceutical R&D may lie in open-source research, with key data being made available to a number of people, including college students and university researchers, in an open and collaborative process.

The future of pharmaceutical R&D may lie in open-source research, with key data being made available to a number of people, including college students and university researchers, in an open and collaborative process.

GlaxoSmithKline Consumer Healthcare, Cephalon UK Ltd, and ProStraken Group plc have been accused of breaching the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice.

Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits.

Recent figures published by the EMA relating to centralized procedure activities for human medicines appear to show a marked slow down in the number of generic product applications started and finalised this year to date.

Members of a UK trade union working at AstraZeneca have voted to strike following cuts in pension benefits.

Recent figures published by the EMA relating to centralized procedure activities for human medicines appear to show a marked slow down in the number of generic product applications started and finalized this year to date (9 and 12, respectively).

Novartis has been told off by the FDA in a letter about a social media Facebook widgit that appears on the company?s Tasigna website.

Merck has received letters from the US Department of Justice and the US Securities and Exchange Commission seeking information about "activities in a number of countries" with reference to the Foreign Corrupt Practices Act.

Merck & Co. (Whitehouse Station, NJ) has received letters from the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) seeking information about "activities in a number of countries" with reference to the Foreign Corrupt Practices Act.

French pharma giant Les Laboratoires Servier SA has been accused of providing "misleading" and "incorrect" information during the EC?s antitrust investigation.

The FDA has approved the first generic version of the blockbuster low molecular weight heparin Lovenox (enoxaparin sodium), much to originator sanofi-aventis's displeasure.

French pharma giant Les Laboratoires Servier SA has been accused of providing "misleading" and "incorrect" information during the EC's antitrust investigation.

Teva and Sun Pharmaceuticals? motion to overturn a verdict issued against them in April 2010 for patent infringement has been denied by a US court, leaving the companies at the mercy of pharma giants Pfizer and Nycomed, who have said they will "vigorously" pursue damage claims.

Researchers claim that a dissolving microneedle patch may be able to offer improved vaccination against influenza compared with traditional needles, and also allow people without medical training to easily and safely administer the vaccine.

Pfizer has been asked by the FDA to suspend chronic pain studies involving tanezumab because of safety concerns.

Teva's and Sun Pharmaceuticals' motion to overturn a verdict issued against them in April 2010 for patent infringement has been denied by a US court, leaving the companies at the mercy of pharma giants Pfizer and Nycomed, who have said they will "vigorously" pursue damage claims.

McNeil Consumer Healthcare, a division of Johnson & Johnson (J&J), has once again expanded the recall of certain OTC products because of a musty or moldy odor, which has been linked to trace amounts of the chemical 2,4,6 triburomoanisole (TBA).

The Council of Europe (CoE) is hoping its 'Medicrime' treaty can help curb the lucrative global trade in fake medicines.

McNeil Consumer Healthcare, a division of Johnson & Johnson (J&J), has once again expanded the recall of certain OTC products because of a musty or moldy odor, which has been linked to trace amounts of the chemical 2,4,6 triburomoanisole (TBA).

The Council of Europe (CoE) is hoping its Medicrime treaty can help curb the lucrative global trade in fake medicines.

Crunch time is rapidly approaching in Roquette?s long-running patent dispute with SPI Pharma, with the case scheduled to go to trial on 4th October 2010.

Eli Lilly has made a move into enzyme replacement therapy by acquiring Alnara Pharmaceuticals, whose pancreatic enzyme replacement therapy, liprotamase, is currently under review by the FDA for the treatment of exocrine pancreatic insufficiency.

The merger Novartis has been trying to unilaterally impose on Alcon cannot go ahead without the approval of Alcon's Independent Director Committee (IDC), according to a legal expert, and at the moment the IDC still believes that Novartis's offer is vastly inadequate.

Teva Pharmaceuticals in the US has admitted to including false statements in the physician prescribing information for its oral contraceptive product Gianvi, a generic version of Bayer Healthcare?s YAZ oral contraceptive.

A new dialogue between governments and the pharma industry is being called for by Andrew Witty, CEO of GlaxoSmithKline and President of EFPIA, to address access to and affordability of European medicines, as well as Europe?s competitiveness as a base for R&D investment.

European pharmaceutical companies are outdoing their US counterparts when it comes to making medicines available to developing countries, according to the Access to Medicine Index, which analyses and ranks the access to medicine efforts of the world?s largest pharma companies.

A new dialogue between governments and the pharma industry is being called for by Andrew Witty, CEO of GlaxoSmithKline and President of EFPIA, to address access to and affordability of European medicines, as well as Europe's competitiveness as a base for R&D investment.

European pharmaceutical companies are outdoing their US counterparts when it comes to making medicines available to developing countries, according to the Access to Medicine Index, which analyzes and ranks the access to medicine efforts of the world's largest pharma companies.

A new form of study for assessing the benefits and risks of medicines has been launched in the EU with the hope of increasing public trust in study findings.